June 21, 2024 07:30 PM Eastern Daylight Time
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
View Full Size
Download
Full Size
JPEG, 1497x206, 98.9 KB
Small
JPEG, 480x66, 36.6 KB
Preview
JPEG, 144x20, 17.1 KB
Thumbnail
JPEG, 120x17, 15.7 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Bristol Myers Squibb Announces U.S. FDA Acceler...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire